Physician profile
David Morrison
NPI 1326027947
$4,204,396.80
in general payments reported to CMS, 2019-2025
9 companies · $381K in 2025
The $381K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $589K · 2020: $550K · 2021: $603K · 2022: $663K · 2023: $730K · 2024: $687K · 2025: $381K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $1.8M · Food and Beverage: $210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $1,798,360.84 |
| Food and Beverage | $210.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $4,203,937.44 | 2019-2025 | Arthrex |
| Pfizer INC. | $257.83 | 2022-2023 | |
| Incyte Corporation | $43.64 | 2020-2024 | Jakafi |
| Sun Pharmaceutical Industries INC. | $38.30 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.41 | 2021 | |
| Dendreon Pharmaceuticals LLC | $30.01 | 2021 | |
| Global Blood Therapeutics, INC. | $21.30 | 2020 | |
| Beigene USA, INC. | $19.50 | 2024 | Brukinsa |
| Beone Medicines USA, INC. | $17.37 | 2025 | Brukinsa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Morrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.